Trial Profile
Ponatinib as second-line treatment in Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2018
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 11 Sep 2018 New trial record
- 01 Sep 2018 Results published in the Annals of Hematology